Is Bristol’s Long-Term Revenue Growth A Potential Salve For Celgene Shareholders?

 
• By Mandy Jackson
  
Sunshine
Without CVR cash, Celgene investors still could see an additional payout via BMS share buybacks and long-term sales growth • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from New Products

More from Scrip